Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)

This study has been completed.
Sponsor:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00000579
First received: October 27, 1999
Last updated: January 2, 2014
Last verified: August 2006
  Purpose

The purposes of this study are to assess rapidly innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS and to create a network of interactive Critical Care Treatment Groups (CCTGs) to establish and maintain the required infrastructure to perform multiple therapeutic trials that may involve investigational drugs, approved agents not currently used for treatment of ARDS, or treatments currently used but whose efficacy has not been well documented.


Condition Intervention Phase
Respiratory Distress Syndrome, Adult
Lung Diseases
Procedure: Low Tidal Volume Ventilation
Procedure: Positive End-Expiratory Pressure
Drug: Lysofylline
Drug: Methylprednisolone
Drug: Ketoconazole
Procedure: Fluid Management
Procedure: Pulmonary Artery Catheter
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Factorial Assignment
Primary Purpose: Treatment
Official Title: Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Primary Outcome Measures:
  • Vary by protocol

Study Start Date: September 1994
Study Completion Date: July 2004
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   13 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women
  • 13 years of age or older
  • ARDS or risk factors for ARDS (patients will be considered at risk if they are critically ill and have trauma, sepsis, shock, pneumonia, inhalation injury, drug overdose, pancreatitis, or hypertransfusion)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000579

  Show 21 Study Locations
Sponsors and Collaborators
Investigators
Principal Investigator: Edward Abraham, MD University of Colorado, Denver
Principal Investigator: Antonio Anzueto, MD University of Texas
Principal Investigator: Roy Brower, MD Johns Hopkins University
Principal Investigator: Alfred F. Connors, MD University of Virginia
Principal Investigator: Bennett P. deBoisblanc, MD Louisiana State University Health Sciences Center in New Orleans
Principal Investigator: Bennett P. deBoisblanc, MD Louisiana State University Health Science Center
Principal Investigator: Michael Donahoe, MD University of Pittsburgh
Principal Investigator: Kalpalatha K. Guntupalli, MD Baylor College of Medicine
Principal Investigator: Robert D. Hite, MD Wake Forest School of Medicine
Principal Investigator: Rolf Hubmayr, MD Mayo Clinic
Principal Investigator: Neil MacIntyre, MD Duke University
Principal Investigator: Michael A. Matthay, MD University of California, San Francisco
Principal Investigator: Alan Morris, MD Latter Day Saints Hospital
Principal Investigator: Michael J. Murray Mayo Foundation
Principal Investigator: James A. Russell, MD University of British Columbia
Principal Investigator: Gregory A. Schmidt, MD, FCCP University of Chicago
Principal Investigator: David A. Schoenfeld, PhD Massachusetts General Hospital
Principal Investigator: Jay S. Steingrub, MD, FCCP Baystate Medical Center
Principal Investigator: Arthur Wheeler, MD Vanderbilt University
Principal Investigator: Herbert Wiedemann, MD Cleveland Clinic Lerner College of Medicine
  More Information

Additional Information:
Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00000579     History of Changes
Other Study ID Numbers: 217, N01 HR16146, N01 HR16147, N01 HR16148, N01 HR16149, N01 HR16150, N01 HR16151, N01 HR16152, N01 HR16153, N01 HR16154, N01 HR16155, N01 HR46054, N01 HR46055, N01 HR46056, N01 HR46057, N01 HR46058, N01 HR46059, N01 HR46060, N01 HR46061, N01 HR46062, N01 HR46063, N01 HR46064, N01 HR56165, N01 HR56166, N01 HR56167, N01 HR56168, N01 HR56169, N01 HR56170, N01 HR56171, N01 HR56172, N01 HR56173, N01 HR56174, N01 HR56175, N01 HR56176, N01 HR56179
Study First Received: October 27, 1999
Last Updated: January 2, 2014
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Lung Diseases
Respiratory Distress Syndrome, Newborn
Respiratory Distress Syndrome, Adult
Acute Lung Injury
Respiratory Tract Diseases
Respiration Disorders
Infant, Premature, Diseases
Infant, Newborn, Diseases
Lung Injury
Ketoconazole
Methylprednisolone acetate
Prednisolone acetate
Methylprednisolone
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone hemisuccinate
Prednisolone phosphate
14-alpha Demethylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antifungal Agents
Anti-Infective Agents
Therapeutic Uses
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents

ClinicalTrials.gov processed this record on April 15, 2014